Tiemann Investment Advisors LLC decreased its position in shares of Pfizer, Inc. (NYSE:PFE) by 1.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,228 shares of the biopharmaceutical company’s stock after selling 208 shares during the period. Tiemann Investment Advisors LLC’s holdings in Pfizer were worth $555,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of PFE. Majedie Asset Management Ltd acquired a new stake in shares of Pfizer during the first quarter valued at $10,689,000. Tredje AP fonden increased its stake in shares of Pfizer by 6.6% in the first quarter. Tredje AP fonden now owns 773,696 shares of the biopharmaceutical company’s stock valued at $26,468,000 after buying an additional 47,630 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in shares of Pfizer by 14.2% in the first quarter. Peapack Gladstone Financial Corp now owns 192,041 shares of the biopharmaceutical company’s stock valued at $6,570,000 after buying an additional 23,951 shares during the last quarter. Stone House Investment Management LLC increased its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 66 shares during the last quarter. Finally, Svenska Handelsbanken AB publ increased its stake in shares of Pfizer by 7.2% in the first quarter. Svenska Handelsbanken AB publ now owns 18,579 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 1,250 shares during the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.
Pfizer, Inc. (NYSE PFE) opened at 32.67 on Friday. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The company has a market capitalization of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00. The firm’s 50-day moving average is $33.30 and its 200-day moving average is $33.38.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s payout ratio is 94.12%.
Several equities research analysts have recently weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price target on shares of Pfizer in a report on Friday. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price target (down from $39.00) on shares of Pfizer in a report on Tuesday. Cowen and Company set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $37.61.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.